ASH 2013 Preview: CAR Modified T Cells, Novel Assays, and Ibrutinib

Silas Inman @silasinman
Published: Wednesday, Dec 04, 2013

“The data that we have now for ALL is that this can now be used for those patients who have failed every other therapy,” van den Brink explained. “In about two-thirds of these patients, we were able to get them again into a remission.”

Many of the side effects associated with the treatment were reversible and included high-grade fevers, hypotension, hypoxia, mental status changes, and seizures. Following treatment with the T cell therapy, 4 patients were able to undergo allogeneic stem cell transplantation and 5 patients were being prepped for transplantation.

“We are using this as a bridge toward transplant, so that these patients will be eligible to receive a life-saving bone marrow transplant,” commented van den Brink. “We think that this therapy holds great promise for ALL”

These studies, plus more, will be discussed December 7-10, 2013, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted TherapiesMar 31, 20181.5
Publication Bottom Border
Border Publication
x